Biophan’s Myo-Vad Could Be Ideal For Battlefield, Bridge To Therapy
This article was originally published in The Gray Sheet
Executive Summary
A cardiac support device simple enough to install on the battlefield could be available in three years, according to Biophan CEO Mike Weiner
You may also be interested in...
Biophan, FDA To Research MRI-Device Compatibility
A research partnership between Biophan Technologies and FDA aims to make it safer for patients with implanted medical devices to undergo magnetic resonance imaging (MRI) procedures
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.